From: Are innovation and new technologies in precision medicine paving a new era in patients centric care?
Drug | Therapeutic area | Biomarker | Labeling sections |
---|---|---|---|
Abacavir | Infectious Diseases | HLA-B | Boxed warning, dosage and administration, contraindications, warnings and precautions |
Abemaciclib (1) | Oncology | ESR (Hormone receptor) | Indications and usage, adverse reactions, clinical studies |
Abemaciclib (2) | Oncology | ERBB2 (HER2) | Indications and usage, adverse reactions, clinical studies |
Ado-Trastuzumab Emtansine | Oncology | ERBB2 (HER2) | Indications and usage, warnings and precautions, adverse reactions, clinical pharmacology, clinical studies |
Afatinib | Oncology | EGFR | Indications and usage, dosage and administration, adverse reactions, clinical studies |
Alectinib | Oncology | ALK | Indications and usage, dosage and administration, adverse reactions, clinical pharmacology, clinical studies |
Amitriptyline | Psychiatry | CYP2D6 | Precautions |
Anastrozole | Oncology | ESR, PGR (Hormone receptor) | Indications and usage, adverse reactions, drug interactions, clinical studies |
Arformoterol (1) | Pulmonary | UGT1A1 | Clinical pharmacology |
Arformoterol (2) | Pulmonary | CYP2D6 | Clinical pharmacology |
Aripiprazole | Psychiatry | CYP2D6 | Dosage and administration, use in specific populations, clinical pharmacology |
Aripiprazole lauroxil | Psychiatry | CYP2D6 | Dosage and administration, use in specific populations, clinical pharmacology |
Arsenic trioxide | Oncology | PML-RARA | Indications and usage |
Atezolizumab | Oncology | CD274 (PD-L1) | Indications and usage, adverse reactions, clinical pharmacology, clinical studies |
Atomoxetine | Psychiatry | CYP2D6 | Dosage and administration, warnings and precautions, adverse reactions, drug interactions, clinical pharmacology |
Ascorbic acid, PEG-3350, potassium chloride, sodium ascorbate, sodium chloride, and sodium sulfate | Gastroenterology | G6PD | Warnings and precautions |
Avatrombopag (1) | Hematology | F2 (Prothrombin) | Warnings and precautions |
Avatrombopag (2) | Hematology | F5 (Factor V Leiden) | Warnings and precautions |
Avatrombopag (3) | Hematology | PROC | Warnings and precautions |
Avatrombopag (4) | Hematology | PROS1 | Warnings and precautions |
Avatrombopag (5) | Hematology | SERPINC1 (Antithrombin III) | Warnings and precautions |
Avelumab | Oncology | CD274 (PD-L1) | Clinical studies |
Azathioprine | Rheumatology | TPMT | Dosage and administration, warnings, precautions, drug interactions, adverse reactions, clinical pharmacology |
Belinostat | Oncology | UGT1A1 | Dosage and administration, clinical pharmacology |
Binimetinib (1) | Oncology | BRAF | Indications and usage, dosage and administration, warnings and precautions, adverse reactions, use in specific populations, clinical studies |
Binimetinib (2) | Oncology | UGT1A1 | Clinical pharmacology |
Blinatumomab | Oncology | BCR-ABL1 (Philadelphia chromosome) | Indications and usage, clinical studies |
Boceprevir | Infectious Diseases | IFNL3 (IL28B) | Clinical pharmacology |
Bosutinib | Oncology | BCR-ABL1 (Philadelphia chromosome) | Indications and usage, adverse reactions, use in specific populations, clinical studies |
Brentuximab vedotin | Oncology | ALK | Clinical studies |
Brexpiprazole | Psychiatry | CYP2D6 | Dosage and administration, use in specific populations, clinical pharmacology |
Brigatinib | Oncology | ALK | Indications and usage, adverse reactions, clinical studies |
Brivaracetam | Neurology | CYP2C19 | Clinical pharmacology |
Busulfan | Oncology | BCR-ABL1 (Philadelphia chromosome) | Clinical studies |
Cabozantinib | Oncology | RET | Clinical studies |
Capecitabine | Oncology | DPYD | Warnings and precautions, patient counseling information |
Carbamazepine (1) | Neurology | HLA-B | Boxed warning, warnings, precautions |
Carbamazepine (2) | Neurology | HLA-A | Warnings |
Carglumic Acid | Inborn errors of metabolism | NAGS | Indications and usage, warnings and precautions, use in specific populations, clinical pharmacology, clinical studies |
Cariprazine | Psychiatry | CYP2D6 | Clinical pharmacology |
Carisoprodol | Rheumatology | CYP2C19 | Use in specific populations, clinical pharmacology |
Carvedilol | Cardiology | CYP2D6 | Drug interactions, clinical pharmacology |
Celecoxib | Rheumatology | CYP2C9 | Dosage and administration, use in specific populations, clinical pharmacology |
Ceritinib | Oncology | ALK | Indications and usage, dosage and administration, adverse reactions, clinical studies |
Cerliponase alfa | Inborn errors of metabolism | TPP1 | Indications and usage, use in specific populations, clinical studies |
Cetuximab (1) | Oncology | EGFR | Indications and usage, dosage and administration, warnings and precautions, adverse reactions, clinical studies |
Cetuximab (2) | Oncology | RAS | Indications and usage, dosage and administration, warnings and precautions, adverse reactions, clinical studies |
Cevimeline | Dental | CYP2D6 | Precautions |
Chloroquine | Infectious diseases | G6PD | Precautions |
Chlorpropamide | Endocrinology | G6PD | Precautions |
Cisplatin | Oncology | TPMT | Adverse reactions |
Citalopram (1) | Psychiatry | CYP2C19 | Dosage and administration, warnings, clinical pharmacology |
Citalopram (2) | Psychiatry | CYP2D6 | Clinical pharmacology |
Clobazam | Neurology | CYP2C19 | Dosage and administration, use in specific populations, clinical pharmacology |
Clomipramine | Psychiatry | CYP2D6 | Precautions |
Clopidogrel | Cardiology | CYP2C19 | Boxed warning, warnings and precautions, clinical pharmacology |
Clozapine | Psychiatry | CYP2D6 | Dosage and administration, use in specific populations, clinical pharmacology |
Cobimetinib | Oncology | BRAF | Indications and usage, dosage and administration, adverse reactions, clinical studies |
Codeine | Anesthesiology | CYP2D6 | Boxed warning, warnings and precautions, use in specific populations, patient counseling information |
Crizotinib (1) | Oncology | ALK | Indications and usage, dosage and administration, adverse reactions, use in specific populations, clinical pharmacology, clinical studies |
Crizotinib (2) | Oncology | ROS1 | Indications and usage, dosage and administration, adverse reactions, use in specific populations, clinical studies |
Dabrafenib (1) | Oncology | BRAF | Indications and usage, dosage and administration, warnings and precautions, adverse reactions, clinical pharmacology, clinical studies, patient counseling information |
Dabrafenib (2) | Oncology | G6PD | Warnings and precautions, adverse reactions, patient counseling information |
Dabrafenib (3) | Oncology | RAS | Dosage and administration, warnings and precautions |
Daclatasvir | Infectious diseases | IFNL3 (IL28B) | Clinical studies |
Dapsone (1) | Dermatology | G6PD | Warnings and precautions, use in specific populations |
Dapsone (2) | Dermatology | Nonspecific (Congenital Methemoglobinemia) | Warnings and precautions |
Dapsone (3) | Infectious Diseases | G6PD | Precautions, adverse reactions, overdosage |
Darifenacin | Urology | CYP2D6 | Clinical pharmacology |
Dasabuvir, ombitasvir, paritaprevir, and ritonavir | Infectious Diseases | IFNL3 (IL28B) | Clinical studies |
Dasatinib | Oncology | BCR-ABL1 (Philadelphia chromosome) | Indications and usage, dosage and administration, warnings and precautions, adverse reactions, clinical studies |
Denileukin diftitox | Oncology | IL2RA (CD25 antigen) | Indications and usage, warnings and precautions, clinical studies |
Desipramine | Psychiatry | CYP2D6 | Precautions |
Desflurane | Anesthesiology | Nonspecific (Genetic Susceptibility to Malignant Hyperthermia) | Contraindications |
Desvenlafaxine | Psychiatry | CYP2D6 | Clinical pharmacology |
Deutetrabenazine | Neurology | CYP2D6 | Dosage and administration, warnings and precautions, use in specific populations, clinical pharmacology |
Dexlansoprazole | Gastroenterology | CYP2C19 | Drug interactions, clinical pharmacology |
Dextromethorphan and quinidine | Neurology | CYP2D6 | Warnings and precautions, clinical pharmacology |
Diazepam | Neurology | CYP2C19 | Clinical pharmacology |
Dinutuximab | Oncology | MYCN | Clinical studies |
Dolutegravir | Infectious Diseases | UGT1A1 | Clinical pharmacology |
Doxepin (1) | Psychiatry | CYP2D6 | Clinical pharmacology |
Doxepin (2) | Psychiatry | CYP2C19 | Clinical pharmacology |
Dronabinol | Gastroenterology | CYP2C9 | Use in specific populations, clinical pharmacology |
Drospirenone and ethinyl estradiol | Gynecology | CYP2C19 | Clinical pharmacology |
Duloxetine | Psychiatry | CYP2D6 | Drug interactions |
Durvalumab | Oncology | CD274 (PD-L1) | Clinical pharmacology, clinical studies |
Efavirenz | Infectious diseases | CYP2B6 | Clinical pharmacology |
Elbasvir and grazoprevir | Infectious diseases | IFNL3 (IL28B) | Clinical studies |
Eliglustat | Inborn errors of metabolism | CYP2D6 | Indications and usage, dosage and administration, contraindications, warnings and precautions, drug interactions, use in specific populations, clinical pharmacology, clinical studies |
Elosulfase | Inborn errors of metabolism | GALNS | Indications and usage, warnings and precautions, use in specific populations, clinical pharmacology, clinical studies |
Eltrombopag (1) | Hematology | F5 (Factor V Leiden) | Warnings and precautions |
Eltrombopag (2) | Hematology | SERPINC1 (Antithrombin III) | Warnings and precautions |
Enasidenib | Oncology | IDH2 | Indications and usage, dosage and administration, clinical pharmacology, clinical studies |
Encorafenib | Oncology | BRAF | Indications and usage, dosage and administration, warnings and precautions, adverse reactions, use in specific populations, clinical pharmacology, clinical studies |
Enflurane | Anesthesiology | Nonspecific (genetic susceptibility to malignant hyperthermia) | Contraindications |
Erlotinib | Oncology | EGFR | Indications and usage, dosage and administration, adverse reactions, clinical studies |
Erythromycin and sulfisoxazole | Infectious Diseases | G6PD | Precautions |
Escitalopram (1) | Psychiatry | CYP2D6 | Drug interactions |
Escitalopram (2) | Psychiatry | CYP2C19 | Adverse reactions |
Esomeprazole | Gastroenterology | CYP2C19 | Drug interactions, clinical pharmacology |
Eteplirsen | Neurology | DMD | Indications and usage, adverse reactions, use in specific populations, clinical studies |
Everolimus (1) | Oncology | ERBB2 (HER2) | Indications and usage, dosage and administration, warnings and precautions, adverse reactions, drug interactions, use in specific populations, clinical studies |
Everolimus (2) | Oncology | ESR (hormone receptor) | Indications and usage, dosage and administration, warnings and precautions, adverse reactions, drug interactions, use in specific populations, clinical studies |
Exemestane | Oncology | ESR, PGR (hormone receptor) | Indications and usage, dosage and administration, clinical studies |
Fesoterodine | Urology | CYP2D6 | Drug interactions, clinical pharmacology |
Flibanserin (1) | Gynecology | CYP2C9 | Clinical pharmacology |
Flibanserin (2) | Gynecology | CYP2C19 | Adverse reactions, use in specific populations, clinical pharmacology |
Flibanserin (3) | Gynecology | CYP2D6 | Clinical pharmacology |
Fluorouracil (1) | Dermatology | DPYD | Contraindications, warnings |
Fluorouracil (2) | Oncology | DPYD | Warnings and precautions, patient counseling information |
Fluoxetine | Psychiatry | CYP2D6 | Precautions, clinical pharmacology |
Flurbiprofen | Rheumatology | CYP2C9 | Clinical pharmacology |
Fluvoxamine | Psychiatry | CYP2D6 | Drug interactions |
Formoterol (1) | Pulmonary | CYP2D6 | Clinical pharmacology |
Formoterol (2) | Pulmonary | CYP2C19 | Clinical pharmacology |
Fulvestrant (1) | Oncology | ERBB2 (HER2) | Indications and usage, adverse reactions, clinical studies |
Fulvestrant (2) | Oncology | ESR, PGR (Hormone Receptor) | Indications and usage, adverse reactions, clinical pharmacology, clinical studies |
Galantamine | Neurology | CYP2D6 | Clinical pharmacology |
Gefitinib (1) | Oncology | EGFR | Indications and usage, dosage and administration, clinical studies |
Gefitinib (2) | Oncology | CYP2D6 | Clinical pharmacology |
Glimepiride | Endocrinology | G6PD | Warnings and precautions, adverse reactions |
Glipizide | Endocrinology | G6PD | Precautions |
Glyburide | Endocrinology | G6PD | Precautions |
Hydralazine | Cardiology | Nonspecific (NAT) | Clinical pharmacology |
Ibrutinib (1) | Oncology | Chromosome 17p | Indications and usage, clinical studies |
Ibrutinib (2) | Oncology | Chromosome 11q | Clinical studies |
Iloperidone | Psychiatry | CYP2D6 | Dosage and administration, warnings and precautions, drug interactions, clinical pharmacology |
Imatinib (1) | Oncology | KIT | Indications and usage, dosage and administration, clinical studies |
Imatinib (2) | Oncology | BCR-ABL1 (Philadelphia chromosome) | Indications and usage, dosage and administration, warnings and precautions, adverse reactions, use in specific populations, clinical pharmacology, clinical studies |
Imatinib (3) | Oncology | PDGFRB | Indications and usage, dosage and administration, clinical studies |
Imatinib (4) | Oncology | FIP1L1-PDGFRA | Indications and usage, dosage and administration, clinical studies |
Imipramine | Psychiatry | CYP2D6 | Precautions |
Indacaterol | Pulmonary | UGT1A1 | Clinical pharmacology |
Inotuzumab Ozogamicin | Oncology | BCR-ABL1 (Philadelphia chromosome) | Clinical studies |
Irinotecan | Oncology | UGT1A1 | Dosage and administration, warnings and precautions, clinical pharmacology |
Isoflurane | Anesthesiology | Nonspecific (genetic susceptibility to malignant hyperthermia) | Contraindications |
Isoniazid, pyrazinamide, and rifampin | Infectious Diseases | Nonspecific (NAT) | Clinical pharmacology |
Isosorbide dinitrate | Cardiology | CYB5R | Overdosage |
Isosorbide mononitrate | Cardiology | CYB5R | Overdosage |
Ivacaftor | Pulmonary | CFTR | Indications and usage, adverse reactions, use in specific populations, clinical pharmacology, clinical studies |
Ivacaftor and lumacaftor | Pulmonary | CFTR | Indications and usage, adverse reactions, use in specific populations, clinical studies |
Ivacaftor and tezacaftor | Pulmonary | CFTR | Indications and usage, adverse reactions, use in specific populations, clinical pharmacology, clinical studies |
Lacosamide | Neurology | CYP2C19 | Clinical pharmacology |
Lansoprazole | Gastroenterology | CYP2C19 | Drug interactions, clinical pharmacology |
Lapatinib (1) | Oncology | ERBB2 (HER2) | Indications and usage, dosage and administration, adverse reactions, use in specific populations, clinical studies |
Lapatinib (2) | Oncology | ESR, PGR (Hormone Receptor) | Indications and usage, dosage and administration, adverse reactions, use in specific populations, clinical studies |
Lapatinib (3) | Oncology | HLA-DQA1, HLA-DRB1 | Clinical pharmacology |
Ledipasvir and sofosbuvir | Infectious diseases | IFNL3 (IL28B) | Clinical studies |
Lenalidomide | Hematology | Chromosome 5q | Boxed warning, indications and usage, adverse reactions, use in specific populations, clinical studies |
Lesinurad | Rheumatology | CYP2C9 | Drug interactions, clinical pharmacology |
Letrozole | Oncology | ESR, PGR (Hormone Receptor) | Indications and usage, adverse reactions, clinical studies |
Lidocaine and prilocaine (1) | Anesthesiology | Nonspecific (congenital methemoglobinemia) | Warnings and precautions |
Lidocaine and prilocaine (2) | Anesthesiology | G6PD | Warnings and precautions, clinical pharmacology |
Lofexidine | Anesthesiology | CYP2D6 | Use in specific populations |
Mafenide | Infectious diseases | G6PD | Warnings, adverse reactions |
Meclizine | Neurology | CYP2D6 | Clinical pharmacology |
Mercaptopurine (1) | Oncology | TPMT | Dosage and administration, warnings and precautions, adverse reactions, clinical pharmacology |
Mercaptopurine (2) | Oncology | NUDT15 | Dosage and administration, warnings and precautions, clinical pharmacology |
Methylene blue | Hematology | G6PD | Contraindications, warnings and precautions |
Metoclopramide (1) | Gastroenterology | CYB5R | Precautions, overdosage |
Metoclopramide (2) | Gastroenterology | G6PD | Precautions, overdosage |
Metoprolol | Cardiology | CYP2D6 | Drug interactions, clinical pharmacology |
Midostaurin (1) | Oncology | FLT3 | Indications and usage, dosage and administration, adverse reactions, clinical studies |
Midostaurin (2) | Oncology | NPM1 | Clinical studies |
Midostaurin (3) | Oncology | KIT | Clinical studies |
Mirabegron | Urology | CYP2D6 | Clinical pharmacology |
Modafinil | Psychiatry | CYP2D6 | Clinical pharmacology |
Mycophenolic acid | Transplantation | HPRT1 | Warnings and precautions |
Nalidixic acid | Infectious diseases | G6PD | Precautions, adverse reactions |
Nebivolol | Cardiology | CYP2D6 | Dosage and administration, clinical pharmacology |
Nefazodone | Psychiatry | CYP2D6 | Precautions |
Neratinib (1) | Oncology | ERBB2 (HER2) | Indications and usage, adverse reactions, clinical studies |
Neratinib (2) | Oncology | ESR, PGR (Hormone Receptor) | Clinical studies |
Nilotinib (1) | Oncology | BCR-ABL1 (Philadelphia chromosome) | Indications and usage, dosage and administration, warnings and precautions, adverse reactions, use in specific populations, clinical studies |
Nilotinib (2) | Oncology | UGT1A1 | Clinical pharmacology |
Niraparib | Oncology | BRCA | Clinical studies |
Nitrofurantoin | Infectious Diseases | G6PD | Warnings, adverse reactions |
Nivolumab (1) | Oncology | BRAF | Indications and usage, adverse reactions, clinical studies |
Nivolumab (2) | Oncology | CD274 (PD-L1) | Clinical pharmacology, clinical studies |
Nivolumab (3) | Oncology | Microsatellite instability, mismatch repair | Indications and usage, use in specific populations, clinical pharmacology, clinical studies |
Nortriptyline | Psychiatry | CYP2D6 | Precautions |
Obinutuzumab | Oncology | MS4A1 (CD20 antigen) | Clinical studies |
Olaparib | Oncology | BRCA | Indications and usage, dosage and administration, warnings and precautions, adverse reactions, clinical studies |
Olaratumab | Oncology | PDGFRA | Clinical studies |
Omacetaxine | Oncology | BCR-ABL1 (Philadelphia chromosome) | Clinical studies |
Ombitasvir, paritaprevir, and ritonavir | Infectious diseases | IFNL3 (IL28B) | Clinical studies |
Omeprazole | Gastroenterology | CYP2C19 | Drug interactions, clinical pharmacology |
Ondansetron | Gastroenterology | CYP2D6 | Clinical pharmacology |
Osimertinib | Oncology | EGFR | Indications and usage, dosage and administration, adverse reactions, clinical studies |
Oxcarbazepine | Neurology | HLA-B | Warnings and precautions |
Palbociclib (1) | Oncology | ESR (Hormone Receptor) | Indications and usage, adverse reactions, clinical studies |
Palbociclib (2) | Oncology | ERBB2 (HER2) | Indications and usage, adverse reactions, clinical studies |
Palonosetron | Gastroenterology | CYP2D6 | Clinical pharmacology |
Panitumumab (1) | Oncology | EGFR | Adverse reactions, clinical pharmacology, clinical studies |
Panitumumab (2) | Oncology | RAS | Indications and usage, dosage and administration, warnings and precautions, adverse reactions, clinical studies |
Pantoprazole | Gastroenterology | CYP2C19 | Clinical pharmacology |
Parathyroid hormone | Inborn errors of metabolism | CASR | Indications and usage, clinical studies |
Paroxetine | Psychiatry | CYP2D6 | Drug interactions |
Pazopanib (1) | Oncology | UGT1A1 | Clinical pharmacology |
Pazopanib (2) | Oncology | HLA-B | Clinical pharmacology |
Peginterferon alfa-2b | Infectious Diseases | IFNL3 (IL28B) | Clinical pharmacology |
Pegloticase | Rheumatology | G6PD | Boxed warning, contraindications, warnings and precautions, patient counseling information |
Pembrolizumab (1) | Oncology | BRAF | Adverse reactions, clinical studies |
Pembrolizumab (2) | Oncology | CD274 (PD-L1) | Indications and usage, dosage and administration, use in specific populations, clinical studies |
Pembrolizumab (3) | Oncology | Microsatellite Instability, Mismatch Repair | Indications and usage, Dosage and administration, use in specific populations, clinical studies |
Perphenazine | Psychiatry | CYP2D6 | Precautions, clinical pharmacology |
Pertuzumab (1) | Oncology | ERBB2 (HER2) | Indications and usage, warnings and precautions, adverse reactions, clinical pharmacology, clinical studies |
Pertuzumab (2) | Oncology | ESR, PGR (Hormone Receptor) | Clinical studies |
Phenytoin (1) | Neurology | CYP2C9 | Clinical pharmacology |
Phenytoin (2) | Neurology | CYP2C19 | Clinical pharmacology |
Phenytoin (3) | Neurology | HLA-B | Warnings |
Pimozide | Psychiatry | CYP2D6 | Dosage and administration, precautions |
Piroxicam | Rheumatology | CYP2C9 | Clinical pharmacology |
Ponatinib | Oncology | BCR-ABL1 (Philadelphia chromosome) | Indications and usage, warnings and precautions, adverse reactions, use in specific populations, clinical studies |
Prasugrel (1) | Cardiology | CYP2C19 | Use in specific populations, clinical pharmacology, clinical studies |
Prasugrel (2) | Cardiology | CYP2C9 | Use in specific populations, clinical pharmacology, clinical studies |
Prasugrel (3) | Cardiology | CYP3A5 | Use in specific populations, clinical pharmacology, clinical studies |
Prasugrel (4) | Cardiology | CYP2B6 | Use in specific populations, clinical pharmacology, clinical studies |
Primaquine (1) | Infectious Diseases | G6PD | Contraindications, warnings, precautions, adverse reactions, overdosage |
Primaquine (2) | Infectious Diseases | CYB5R | Precautions, adverse reactions |
Propafenone | Cardiology | CYP2D6 | Dosage and administration, warnings and precautions, drug interactions, clinical pharmacology |
Propranolol | Cardiology | CYP2D6 | Clinical pharmacology |
Protriptyline | Psychiatry | CYP2D6 | Precautions |
Quinidine | Cardiology | CYP2D6 | Precautions |
Quinine sulfate (1) | Infectious Diseases | G6PD | Contraindications |
Quinine sulfate (2) | Infectious Diseases | CYP2D6 | Drug interactions |
Rabeprazole | Gastroenterology | CYP2C19 | Clinical pharmacology |
Raltegravir | Infectious Diseases | UGT1A1 | Clinical pharmacology |
Rasburicase (1) | Oncology | G6PD | Boxed warning, contraindications, warnings and precautions |
Rasburicase (2) | Oncology | CYB5R | Boxed warning, contraindications, warnings and precautions |
Ribociclib (1) | Oncology | ESR, PGR (Hormone Receptor) | Indications and usage, clinical studies |
Ribociclib (2) | Oncology | ERBB2 (HER2) | Indications and usage, clinical studies |
Risperidone | Psychiatry | CYP2D6 | Drug interactions, clinical pharmacology |
Rituximab | Oncology | MS4A1 (CD20 antigen) | Indications and usage, dosage and administration, adverse reactions, use in specific populations, clinical studies |
Rosuvastatin | Endocrinology | SLCO1B1 | Clinical pharmacology |
Rucaparib (1) | Oncology | BRCA | Indications and usage, dosage and administration, adverse reactions, use in specific populations, clinical studies |
Rucaparib (2) | Oncology | CYP2D6 | Clinical pharmacology |
Rucaparib (3) | Oncology | CYP1A2 | Clinical pharmacology |
Sevoflurane | Anesthesiology | Nonspecific (Genetic Susceptibility to Malignant Hyperthermia) | Warnings |
Simeprevir | Infectious Diseases | IFNL3 (IL28B) | Clinical pharmacology, clinical studies |
Sodium nitrite | Toxicology | G6PD | Warnings and precautions |
Sofosbuvir | Infectious Diseases | IFNL3 (IL28B) | Clinical studies |
Sofosbuvir and velpatasvir | Infectious Diseases | IFNL3 (IL28B) | Clinical studies |
Sofosbuvir, velpatasvir, and voxilaprevir | Infectious Diseases | IFNL3 (IL28B) | Clinical studies |
Succimer | Hematology | G6PD | Clinical pharmacology |
Succinylcholine | Anesthesiology | BCHE | Warnings, precautions |
Sulfamethoxazole and trimethoprim (1) | Infectious Diseases | G6PD | Precautions |
Sulfamethoxazole and trimethoprim (2) | Infectious Diseases | Nonspecific (NAT) | Precautions |
Sulfasalazine (1) | Gastroenterology | G6PD | Precautions |
Sulfasalazine (2) | Gastroenterology | Nonspecific (NAT) | Clinical pharmacology |
Tamoxifen (1) | Oncology | ESR, PGR (Hormone receptor) | Indications and usage, precautions, adverse reactions, clinical studies |
Tamoxifen (2) | Oncology | F5 (Factor V Leiden) | Warnings |
Tamoxifen (3) | Oncology | F2 (Prothrombin) | Warnings |
Telaprevir | Infectious Diseases | IFNL3 (IL28B) | Clinical pharmacology, clinical studies |
Tetrabenazine | Neurology | CYP2D6 | Dosage and administration, warnings and precautions, use in specific populations, clinical pharmacology |
Thioguanine (1) | Oncology | TPMT | Dosage and administration, warnings, precautions, clinical pharmacology |
Thioguanine (2) | Oncology | NUDT15 | Dosage and administration, warnings, precautions, clinical pharmacology |
Thioridazine | Psychiatry | CYP2D6 | Contraindications, warnings, precautions |
Ticagrelor | Cardiology | CYP2C19 | Clinical pharmacology |
Tolterodine | Urology | CYP2D6 | Precautions, clinical pharmacology |
Tramadol | Anesthesiology | CYP2D6 | Boxed warning, warnings, precautions, use in specific populations, clinical pharmacology |
Trametinib (1) | Oncology | BRAF | Indications and usage, dosage and administration, adverse reactions, clinical pharmacology, clinical studies, patient counseling information |
Trametinib (2) | Oncology | G6PD | Adverse reactions |
Trametinib (3) | Oncology | RAS | Warnings and precautions |
Trastuzumab (1) | Oncology | ERBB2 (HER2) | Indications and usage, warnings and precautions, clinical pharmacology, clinical studies |
Trastuzumab (2) | Oncology | ESR, PGR (Hormone receptor) | Clinical studies |
Tretinoin | Oncology | PML-RARA | Indications and usage, warnings, clinical pharmacology |
Trimipramine | Psychiatry | CYP2D6 | Precautions |
Umeclidinium | Pulmonary | CYP2D6 | Clinical pharmacology |
Ustekinumab | Dermatology and gastroenterology | IL12A, IL12B, IL23A | Warnings and precautions |
Valbenazine | Neurology | CYP2D6 | Dosage and administration, warnings and precautions, use in specific populations, clinical pharmacology |
Valproic acid (1) | Neurology | POLG | Boxed warning, contraindications, warnings and precautions |
Valproic acid (2) | Neurology | Nonspecific (urea cycle disorders) | Contraindications, warnings and precautions |
Vemurafenib (1) | Oncology | BRAF | Indications and usage, dosage and administration, warnings and precautions, adverse reactions, use in specific populations, clinical pharmacology, clinical studies, patient counseling information |
Vemurafenib (2) | Oncology | RAS | Warnings and precautions, adverse reactions |
Venlafaxine | Psychiatry | CYP2D6 | Precautions |
Venetoclax | Oncology | Chromosome 17p | Indications and usage, dosage and administration, use in specific populations, clinical studies |
Voriconazole | Infectious Diseases | CYP2C19 | Clinical pharmacology |
Vortioxetine | Psychiatry | CYP2D6 | Dosage and administration, clinical pharmacology |
Warfarin (1) | Hematology | CYP2C9 | Dosage and administration, drug interactions, clinical pharmacology |
Warfarin (2) | Hematology | VKORC1 | Dosage and administration, clinical pharmacology |
Warfarin (3) | Hematology | PROS1 | Warnings and precautions |
Warfarin (4) | Hematology | PROC | Warnings and precautions |